Boston Scientific Co. (NYSE:BSX) Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 3.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 908,647 shares of the medical equipment provider’s stock after purchasing an additional 27,400 shares during the quarter. Public Sector Pension Investment Board owned about 0.06% of Boston Scientific worth $76,145,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after acquiring an additional 173,034 shares during the period. BDF Gestion bought a new stake in shares of Boston Scientific in the 2nd quarter worth $3,570,000. Cetera Advisor Networks LLC raised its stake in shares of Boston Scientific by 11.8% in the 1st quarter. Cetera Advisor Networks LLC now owns 201,426 shares of the medical equipment provider’s stock worth $13,796,000 after buying an additional 21,252 shares in the last quarter. Brookstone Capital Management raised its stake in shares of Boston Scientific by 389.1% in the 2nd quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider’s stock worth $5,414,000 after buying an additional 55,645 shares in the last quarter. Finally, HWG Holdings LP bought a new position in Boston Scientific during the second quarter valued at about $482,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.6 %

Boston Scientific stock opened at $90.76 on Thursday. Boston Scientific Co. has a 12 month low of $53.93 and a 12 month high of $91.93. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a market cap of $133.76 billion, a P/E ratio of 75.01, a P/E/G ratio of 2.63 and a beta of 0.79. The company’s fifty day simple moving average is $86.43 and its 200-day simple moving average is $80.51.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the transaction, the executive vice president now owns 34,748 shares in the company, valued at $2,913,967.28. This represents a 16.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 328,157 shares of company stock worth $27,894,270. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several research reports. Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Evercore ISI boosted their target price on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James increased their target price on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research note on Wednesday, September 4th. Morgan Stanley upped their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Finally, TD Cowen raised their price objective on Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.